Get the Daily Brief
Latest Biotech News
UK ups drug spending to dodge U.S. tariffs: pricing deal struck
The U.K. government agreed to loosen drug-price controls and increase medicine spending in return for a three‑year exemption from potential U.S. tariffs on British pharmaceuticals under Section...
China approves Innovent’s picankibart: first domestic IL‑23p19
China’s National Medical Products Administration authorized Innovent Biologics’ picankibart (IBI‑112), branded Pecondle, for moderate to severe plaque psoriasis—marking the country’s first...
Generate:Biomedicines moves TSLP antibody into Phase 3
Generate:Biomedicines announced initiation of two large Phase 3 trials for its lead TSLP antibody, advancing the company’s first program from discovery to pivotal development. The move underscores...
FDA clears Ideaya IND for IDE‑034: bispecific ADC enters clinic
Ideaya Biosciences received FDA clearance to begin a Phase I trial of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 linked to a TOP1 payload, for solid tumors. The...
Singapore’s PRECISE taps pharma majors: Asian genomics alliance
Precision Health Research, Singapore (PRECISE) formalized a precompetitive partnership with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from PRECISE‑SG100K, a population...
Janux reports 30% response rate in early JANX007 prostate data
Janux Therapeutics disclosed a new data cut from its Phase 1 study of JANX007, a T‑cell engager for prostate cancer, showing a 30% objective response rate in the evaluated cohort. The company...
Protego raises $130M — gears up for pivotal AL amyloidosis trial
Protego Biopharma closed an oversubscribed $130 million financing to advance its first‑in‑class oral program for light‑chain (AL) amyloidosis into a potential pivotal study next year. The round...
Regeneron commits $150M... Tessera deal targets gene writing for AATD
Regeneron Pharmaceuticals and Tessera Therapeutics struck a collaboration valued at $150 million to develop and commercialize TSRA‑196, Tessera’s in‑vivo gene‑writing candidate for alpha‑1...
Belite’s Phase 3 win — tinlarebant clears primary endpoint in Stargardt
Belite Bio reported topline results from the global Phase 3 DRAGON trial showing that tinlarebant met the study’s primary endpoint in adolescents with Stargardt disease type 1 (STGD1). The company...
Generate:Biomedicines launches Phase 3 — TSLP antibody moves to registrational studies
Generate:Biomedicines announced the start of two large Phase 3 trials for its lead TSLP (thymic stromal lymphopoietin) antibody, marking a key clinical inflection for the AI‑driven biotech. The...
Circular Genomics closes $15M Series A — circRNA blood biomarker for Alzheimer’s
Circular Genomics raised $15 million in a Series A round led by Mountain Group Partners to advance a circular RNA (circRNA)‑based biomarker platform for early detection of Alzheimer’s disease. The...
Morphocell extends Series A with $50M — scales tissue‑engineered liver programs
Morphocell Technologies announced a $50 million Series A financing extension — a $10 million add‑on to its earlier $40 million close — led by Investissement Québec with participation from CDP...
Analysts initiate coverage on BillionToOne — banks set bullish price targets
JP Morgan, BTIG and Jefferies initiated analyst coverage on molecular diagnostics firm BillionToOne, assigning a range of ratings and price targets that reflect optimism about the company’s...
Ideaya wins IND clearance — IDE‑034 poised for first‑in‑human solid tumor study
Ideaya Biosciences received FDA IND clearance to begin a Phase I study of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 coupled to a TOP1 payload, in patients with advanced...
RNAi therapeutic shows functional‑cure promise for chronic hepatitis B
A study published in Nature Communications reports that a novel RNA interference (RNAi) therapeutic produced results consistent with a functional cure for chronic hepatitis B in preclinical and...
Regeneron bets $150M on Tessera’s gene writing: partnership signed
Regeneron struck a $150 million partnership with gene-writing startup Tessera Therapeutics to accelerate Tessera’s platform toward clinical testing. The deal expands Regeneron’s commitment to...
Protego raises $130M to advance oral amyloidosis candidate – pivotal trial planned
Protego Biopharma closed a $130 million financing to support a potential pivotal study of its oral small molecule for light chain (AL) amyloidosis. Investors behind the round include executives...
Generate:Biomedicines launches two Phase 3 trials for TSLP antibody – AI-designed drug advances
Generate:Biomedicines announced it is initiating two Phase 3 studies of its lead TSLP (thymic stromal lymphopoietin) antibody, marking a major clinical inflection for an AI‑driven biotech. The...
Belite wins Phase 3 for Stargardt drug – U.S. filing now in sight
Belite Bio reported a Phase 3 victory for tinlarebant in adolescents with Stargardt disease, meeting the trial’s primary endpoint and clearing a major regulatory hurdle. The result strengthens...
RNAi therapy shows functional‑cure potential for chronic hepatitis B in Nature Communications
Researchers reported a novel RNA interference (RNAi) therapeutic that produced results consistent with a functional cure for chronic hepatitis B (HBV) in preclinical and early clinical evaluation,...